Identification of Biomarkers, New Treatments, and Vaccines for COVID-19

1. Auflage 2021
ISBN: 978-3-030-71696-7
Verlag: Springer International Publishing

Buch, Englisch, 234 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 663 g

Reihe: Proteomics, Metabolomics, Interactomics and Systems Biology

The novel coronavirus 2019 (COVID-19) has caused a serious global pandemic in just one year. Nearly every country and territory in the world has been affected by the virus. The virulence and infection rate of the virus are profound, and has required extreme social distancing measures across the globe in order to prevent overwhelming the healthcare services and hospitals. COVID-19 appears to have the greatest effects on elderly individuals and those who have co-morbid diseases, such as diabetes and obesity. As the cases and death rate remain high, there are justified fears of this virus remaining for several months or years to come. To address this, a rapid and unprecedented worldwide mobilization effort has begun to identify effective treatments and develop vaccines. As these begin to be deployed and administered across the globe, many now feel the virus will be brought under control and lives will eventually return to normal.

This new volume will increase readers’understanding of the ongoing COVID-19 pandemic through a series of chapters that address these concerns. Leading experts will discuss new treatment approaches, vaccine development, mental health aspects of the pandemic, and convey the results of survey studies. The book will be an excellent resource for researchers studying virology, metabolic diseases, respiratory disorders, and clinical scientists, physicians, drug companies, and healthcare services and workers.

Zielgruppe

Research

Autoren/Hrsg.

Guest, Paul C.

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Medizinische Mikrobiologie & Virologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Naturwissenschaften Biowissenschaften Virologie

Inhaltsverzeichnis

1. Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement.- 2. Prevalence of COVID-19 and the Continued Citizen-based Control in Japan.- 3. COVID-19 Pandemicin Brazil: History, Characteristics, and Evolution.- 4. The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study.- 5. Age-specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons.- 6. Sex differences and COVID-19.- 7. Intestinal Microbiota in the Sars-Cov2 Infection: What is known?.- 8. SARS-CoV-2 Infection and the Kidneys: an Evolving Picture.- 9. Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information.- 10. How do we Manage Breastfeeding during the COVID-19 Pandemic?.- 11. Deep Learning Analysis in Prediction of COVID-19 Infection Status using Chest CT Scan Features.- 12. Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review.- 13. COVID-19, Coenzyme Q10 and Selenium.- 14. Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).- 15. Cinnamon: A Promising Natural Product against COVID-19.- 16. Curcumin and Piperine in COVID-19: a Promising Duo to the Rescue.- 17. Association of in-hospital use of statins, aspirin and renin-angiotensin-aldosterone inhibitors with mortality and ICU admission due to COVID-19A.- 18. The Worldwide Effort to Develop Vaccines for COVID-19.

Über Autor(innen)

Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 38 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and age-related diseases such as diabetes, cancer, cardiovascular disorders, sarcopenia and Alzheimer’s disease.